Handelsavisen
prelaunch
Companies Healthcare SFOODS.HE
SF
SFOODS.HE Nasdaq Helsinki Biotechnology & Medical Research

Solar Foods Oyj

€4,84
Open in Charts → Attach watcher ⌖
EUR
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
P/E
EV / Rev
Div yield
0,00 %
Op margin
-8 415,2 %
ROE
-100,1 %
Net margin
-9 319,2 %
Debt / equity
1,47
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
Ex-dividend
TR 1Y
About

Solar Foods Oyj is a Finnish company that produces protein from air using a patented fermentation process, primarily targeting the food and feed industries.

Business. Solar Foods Oyj (SFOODS.HE) is a biotechnology and medical research company engaged in healthcare diagnostics. The firm is headquartered in Finland and primarily listed on the Nasdaq Helsinki exchange. Specific details regarding operating segments and geographic revenue mix are not available.

Classification92 %
SectorHealthcare
Business sectorPharmaceuticals & Medical Research
IndustryBiotechnology & Medical Research
ActivityHealthcare Diagnostics
Generated · model-assisted
Sell-side consensus
SELL1 analysts
0 buy0 hold1 sell
Avg 12m price target4,67

Analyst recommendations

1 analysts · consensus Sell
Buy0
Hold0
Sell1
12-month price target
4,67
Consensus of sell-side coverage.
Upcoming events
— missing data
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
Sell
1 analysts · indicative
Ownership
not yet wired
Profitability
-100,1 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning SFOODS.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to SFOODS.HE. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    Solar Foods Oyj (SFOODS.HE) is a biotechnology and medical research company engaged in healthcare diagnostics. The firm is headquartered in Finland and primarily listed on the Nasdaq Helsinki exchange. Specific details regarding operating segments and geographic revenue mix are not available.

    Classification92 %
    SectorHealthcare
    Business sectorPharmaceuticals & Medical Research
    IndustryBiotechnology & Medical Research
    ActivityHealthcare Diagnostics
    AI synthesis
    GENERATED

    Solar Foods Oyj has a liquidity position that is relatively strong, with a current ratio of 2.56, indicating that the company has more than twice the current assets to cover its current liabilities. However, the company's liquidity is constrained by a negative net cash position after subtracting total debt, which is a key flag in the risk assessment. The company's cash and equivalents amount to EUR 7,989,830, while its long-term debt is EUR 16,865,000, resulting in a net cash outflow of EUR 8,875,170.

    The company's profitability is currently negative, with a return on equity of -1.0008 and a return on assets of -0.3669, both of which are significantly below the industry median for biotechnology and medical research firms. The operating income is negative at EUR -10,400,340, and the net income is also negative at EUR -11,517,600, indicating that the company is not yet generating positive returns for its shareholders.

    Solar Foods operates in a single business segment focused on producing protein from air, with no disclosed geographic diversification in its revenue streams. The company's revenue for the latest period is EUR 123,590, which is relatively small in scale, and there is no indication of significant geographic expansion or diversification in the near term.

    The company's growth trajectory is uncertain, with no clear indication of revenue growth in the current fiscal year or the next. The operating cash flow is negative at EUR -2,129,970, and the free cash flow is also negative at EUR -8,295,270, suggesting that the company is not generating sufficient cash to fund its operations or expansion. The capital expenditure of EUR -6,239,000 indicates that the company is investing in its operations, but the negative cash flows suggest that these investments are not yet yielding returns.

    The risk assessment for Solar Foods highlights a medium liquidity risk and a low dilution risk. The company's debt-to-equity ratio of 1.47 indicates that it is leveraged, but the dilution risk is low, with no significant dilution expected in the near term. The company's capital structure is dominated by long-term debt, which could pose a risk if interest rates rise or if the company is unable to service its debt obligations.

    Recent events and disclosures indicate that the company is in a development phase, with no strong buy recommendations from analysts. The mean price target is EUR 4.67, with a high of EUR 5.30 and a low of EUR 4.05, suggesting a relatively narrow range of expectations among analysts. The company has not received any strong buy or buy ratings, with all analyst recommendations being neutral or hold.

    Key takeaways
    • Solar Foods Oyj is a biotechnology company producing protein from air, with a current revenue of EUR 123,590.
    • The company has a negative return on equity of -1.0008 and a negative return on assets of -0.3669, indicating poor profitability.
    • The company's liquidity is constrained by a negative net cash position after subtracting total debt, with a current ratio of 2.56.
    • The company is not generating positive cash flows, with a negative operating cash flow of EUR -2,129,970 and a negative free cash flow of EUR -8,295,270.
    • Analysts have not issued any strong buy or buy recommendations, with a mean price target of EUR 4.67.

    Bull / Bear case

    Generated · model-assisted
    — missing data

    In focus — financials by report

    Valuation

    Market price
    €4,84
    Market cap
    Enterprise value
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    P / Tangible book
    Tangible book
    €11.5M
    Net cash
    -€8.9M
    Current ratio
    2.6
    Debt / equity
    1.5
    ROA
    -36.7%
    ROE
    -1.0%
    Cash conversion
    18.0%
    CapEx / revenue
    -50.5%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Next quarternear-term
    Earnings · next quarterconf 45 %
    EPS
    Consensus EPS
    -0,02
    Predicted surprise
    +0,00
    Beat probability
    45 %
    Analysts
    1
    Other metrics
    Revenue
    no estimate
    Segment revenue
    no estimate
    Margin
    no estimate
    Segment margin
    no estimate
    as of 2026-05-24 · Earnings Surprise V1
    Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.
    Full fiscal year~1 year ahead
    Full fiscal year · our forecast vs guidance vs consensus
    MetricOur forecastGuidanceConsensus
    EPSno estimateno estimate-0,02
    Revenueno estimateno estimate2,5M EUR
    Operating incomeno estimateno estimate-2,5M EUR
    Full-year consensus mean (period as reported by source) · consensus in EUR. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.
    Probabilistic model output — not investment advice. · generated 2026-08-04

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Consensus distribution

    sell-side coverage
    Recommendation distribution1 analysts
    Strong buy0
    Buy0
    Hold0
    Sell1
    Strong sell0
    12-month price target€4,67 · Median €4,67
    Low €4,05High €5,30
    Operating income · consensus-2,5M EUR
    EPS surprise
    −2 250,0 %
    reported vs consensus · miss
    Revenue surprise
    −95,0 %
    reported vs consensus · miss

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    Low€4,05
    Mean€4,67
    Median€4,67
    High€5,30
    Spot€4,84
    −3.4 %implied to mean12-month sell-side price targets · ▲ spot

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    Op Margin-8 415,2 %Bottom quartile
    Net Margin-9 319,2 %Bottom quartile
    ROE-100,1 %Bottom quartile
    Capex / Rev-5 048,1 %Bottom quartile
    D/E1,47Bottom quartile
    Cash Conv0,18Bottom quartile

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Capex To Revenue
      capital_expenditure / revenue
    • Return On Equity
      net_income / total_equity
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    Source documents
    • Solar Foods Oyj Market data — financials · 2026-05-29
    • Solar Foods Oyj Market data — analyst estimates · 2026-05-29

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    SFOODS.HECanonical
    Nasdaq Helsinki · EUR

    Intel & risk

    PredictorBeat prob45 %Surprise+0,00Full forecast →
    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage